According to CMS, the model will include: Centralized processes for claims adjudication and payment to pharmacies Coordination with Part D plans, providers, and pharmacies Administrative structures intended to support consistent beneficiary access This approach represents a departure from traditional Part D benefit design by standardizing cost-sharing for a specific class of medications
I collaborated with the Noom team to design and roll out Nooms first-ever offering of oral medicationMetforminas part of its mission to provide accessible weight-loss solutions
Omega-3 fatty acids (EPA, DHA, ALA) are fat-soluble nutrients requiring dietary fats for optimal absorption across the intestinal epithelium
Pancreatic alpha-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation
According to the Diabetes Fact Sheet 2025, approximately half of Korean diabetes patients are obese, with 61.1 percent of those suffering from abdominal obesity
Liraglutide is associated with a slightly higher risk of nausea, while Semaglutide may present a more favorable safety profile in some patients